FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004407766> ?p ?o ?g. }

• W2004407766 abstract "To the Editor: We read with interest the results of this clinical study by Golombick et al. [1]. This and two previous articles from the same authors show that in some, but not all patients with monoclonal gammopathies, the paraprotein load, urinary bone turnover, and the free light chain ratio (FLCr), prognostic factors for progression of disease, did moderately improve. Although the results are hopeful and the medico-scientific world looked forward to the recent follow-up of the previous studies, they also indicate that it is still unclear which criteria would allow to preselect responsive patients so that trials could become more meaningful. Curcumin had been chosen by the authors because of its capacity to down-regulate interleukin-6 (IL-6), an inflammatory cytokine, known to be associated to indicators of systemic inflammation such as C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR). Curcumin has been known for centuries in India as an anti-inflammatory compound and long-term curcumin intake significantly reduces CRP levels [2]. There is consequently reason to speculate that the observed response to curcumin might be associated to the presence of inflammation. This is especially true as inflammation-related microenvironmental factors may locally sustain ongoing lymphoproliferation and B cell transformation [3]. Regrettably, however, neither IL-6 nor CRP or ESR levels, associated to an unfavorable prognosis, have been reported. In case the authors are in the possession of data on IL-6, CRP, or ESR, it would be very easy to verify whether or not their results gain in statistical significance when the presence of inflammation at baseline is used as a patient selection criterion. Even if for none of these indicators data would be available, it might still be tempted to gain insight on the basis of existing results. Absolute levels of FLCs rather than their ratio have recently been suggested as potential biomarkers of immune stimulation and inflammation. CRP appears to be a most relevant indicator in acute illnesses. However, in cases where the CRP response is limited it appears associated to FLC levels [4]. Stratification of the available data according to the absolute levels of uninvolved FLCs (uFLCs) might, therefore, be used in an attempt to verify whether there is an association between the response of the three prognostic factors used to curcumin and the baseline level of uFLCs. If such an association is found and if the response of the three markers is coherent, uFLCs levels might serve as a criterion for patient selection in future trials on curcumin for monoclonal gammopathy of undetermined significance (MGUS) and thereby improve their statistical significance. Curcumin has given some hope to doctors and patients because it is relatively nontoxic in healthy people. Nevertheless, there are reasons for concern about safety in patients with monoclonal gammopathies [5]. As stated by the authors, curcumin may benefit some but not all patients with high risk MGUS. A rapid identification of the subgroup of patients who could benefit from curcumin treatment would be appreciated by all concerned. We, therefore, eagerly look forward to the above suggested further elaboration by the authors on the interesting results of their study [1]. Alphons J. M. Vermorken*, Jingjing Zhu*, Willem J. M. Van de Ven*, Emmanuel Andrès , * Department of Human Genetics, Laboratory for Molecular Oncology, KU Leuven, Belgium, Department of Internal Medicine, Diabetes and Metabolic Disorders, University Hospital of Strasbourg, Strasbourg, France." @default.
• W2004407766 created "2016-06-24" @default.
• W2004407766 creator A5006410108 @default.
• W2004407766 creator A5026993413 @default.
• W2004407766 creator A5045913840 @default.
• W2004407766 creator A5082063900 @default.
• W2004407766 date "2012-06-20" @default.
• W2004407766 modified "2023-10-16" @default.
• W2004407766 title "Comment on: Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: A randomized, double-blind placebo-controlled crossover 4g study and an open-label 8g extension study" @default.
• W2004407766 cites W2018931405 @default.
• W2004407766 cites W2041544048 @default.
• W2004407766 cites W2061037729 @default.
• W2004407766 cites W2121797150 @default.
• W2004407766 cites W2136160261 @default.
• W2004407766 doi "https://doi.org/10.1002/ajh.23276" @default.
• W2004407766 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22718517" @default.
• W2004407766 hasPublicationYear "2012" @default.
• W2004407766 type Work @default.
• W2004407766 sameAs 2004407766 @default.
• W2004407766 citedByCount "0" @default.
• W2004407766 crossrefType "journal-article" @default.
• W2004407766 hasAuthorship W2004407766A5006410108 @default.
• W2004407766 hasAuthorship W2004407766A5026993413 @default.
• W2004407766 hasAuthorship W2004407766A5045913840 @default.
• W2004407766 hasAuthorship W2004407766A5082063900 @default.
• W2004407766 hasConcept C126322002 @default.
• W2004407766 hasConcept C142724271 @default.
• W2004407766 hasConcept C143998085 @default.
• W2004407766 hasConcept C159654299 @default.
• W2004407766 hasConcept C163864487 @default.
• W2004407766 hasConcept C203014093 @default.
• W2004407766 hasConcept C204787440 @default.
• W2004407766 hasConcept C27081682 @default.
• W2004407766 hasConcept C2776364478 @default.
• W2004407766 hasConcept C2776914184 @default.
• W2004407766 hasConcept C2777250017 @default.
• W2004407766 hasConcept C2778143017 @default.
• W2004407766 hasConcept C2778250585 @default.
• W2004407766 hasConcept C2781195455 @default.
• W2004407766 hasConcept C542903549 @default.
• W2004407766 hasConcept C71924100 @default.
• W2004407766 hasConcept C90924648 @default.
• W2004407766 hasConcept C98274493 @default.
• W2004407766 hasConceptScore W2004407766C126322002 @default.
• W2004407766 hasConceptScore W2004407766C142724271 @default.
• W2004407766 hasConceptScore W2004407766C143998085 @default.
• W2004407766 hasConceptScore W2004407766C159654299 @default.
• W2004407766 hasConceptScore W2004407766C163864487 @default.
• W2004407766 hasConceptScore W2004407766C203014093 @default.
• W2004407766 hasConceptScore W2004407766C204787440 @default.
• W2004407766 hasConceptScore W2004407766C27081682 @default.
• W2004407766 hasConceptScore W2004407766C2776364478 @default.
• W2004407766 hasConceptScore W2004407766C2776914184 @default.
• W2004407766 hasConceptScore W2004407766C2777250017 @default.
• W2004407766 hasConceptScore W2004407766C2778143017 @default.
• W2004407766 hasConceptScore W2004407766C2778250585 @default.
• W2004407766 hasConceptScore W2004407766C2781195455 @default.
• W2004407766 hasConceptScore W2004407766C542903549 @default.
• W2004407766 hasConceptScore W2004407766C71924100 @default.
• W2004407766 hasConceptScore W2004407766C90924648 @default.
• W2004407766 hasConceptScore W2004407766C98274493 @default.
• W2004407766 hasIssue "10" @default.
• W2004407766 hasLocation W20044077661 @default.
• W2004407766 hasLocation W20044077662 @default.
• W2004407766 hasOpenAccess W2004407766 @default.
• W2004407766 hasPrimaryLocation W20044077661 @default.
• W2004407766 hasRelatedWork W115137046 @default.
• W2004407766 hasRelatedWork W2020438591 @default.
• W2004407766 hasRelatedWork W2047565570 @default.
• W2004407766 hasRelatedWork W2090363187 @default.
• W2004407766 hasRelatedWork W2131691150 @default.
• W2004407766 hasRelatedWork W2972050921 @default.
• W2004407766 hasRelatedWork W3028811136 @default.
• W2004407766 hasRelatedWork W4210246555 @default.
• W2004407766 hasRelatedWork W68418842 @default.
• W2004407766 hasRelatedWork W3029465886 @default.
• W2004407766 hasVolume "87" @default.
• W2004407766 isParatext "false" @default.
• W2004407766 isRetracted "false" @default.
• W2004407766 magId "2004407766" @default.
• W2004407766 workType "article" @default.